{
    "Trade/Device Name(s)": [
        "STRATIFY JCV DxSelectTM",
        "JCV ELISA"
    ],
    "Submitter Information": "Focus Diagnostics, Inc.",
    "510(k) Number": "K120986",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "OYP"
    ],
    "Summary Letter Date": "August 3, 2012",
    "Summary Letter Received Date": "August 6, 2012",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.3336"
    ],
    "Regulation Name(s)": [
        "John Cunningham Virus serological reagents"
    ],
    "Analyte Class(es)": [
        "virology",
        "serology"
    ],
    "Analyte(s)": [
        "Antibodies to JC virus (John Cunningham Virus)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Microtiter plate (ELISA)"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme-linked immunosorbent assay (ELISA)",
        "Spectrophotometric detection"
    ],
    "Methodologies": [
        "Detection ELISA",
        "Confirmation ELISA"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Focus Diagnostics STRATIFY JCV DxSelect ELISA assay for qualitative detection of antibodies to JC virus in human serum or plasma for risk stratification of progressive multifocal leukoencephalopathy in multiple sclerosis patients considering natalizumab therapy.",
    "Indications for Use Summary": "Qualitative detection of antibodies to JC virus in human serum or plasma, used in conjunction with other clinical data to aid risk stratification for progressive multifocal leukoencephalopathy development in multiple sclerosis patients receiving or considering natalizumab therapy.",
    "fda_folder": "Microbiology"
}